Skip to main content
. 2022 Aug 5;17(17):e202200291. doi: 10.1002/cmdc.202200291

Table 1.

Synthesis and activity of peptides.

Toxicity[b] IC50/μM

Hemolysis[c] HC50/μM

MIC[d] μg/mL

CD[e]

% Vesicle leakage[f]

nr.

Sequence[a]

HeLa

HEK 293

hRBC

PAO1

A. baumannii

% α‐helix

PC

PG

A1

FAKKFFKKFAKFAFK

8.2±0.5

15±0.7

>200

8

8

72

79

43

A2

WFKRILKYLKKLV

8.4±0.5

7.8±0.2

60±8

8

4

66

78

29

A3

WLNALKKILGHLIRH

8.2±0.8

13±0.7

30±5

16

4

79

100

37

A4

KYLKYLVRLVGRLYR

12±1.4

13±1.1

61±10

16

4

68

96

56

A5

WKRIVRIIRWIRKYY

18±0.2

14±0.6

93±4

>16

>16

74

100

46

A6

FAARILRAWFRFLRR

11±2

7.5±0.5

23±2

>16

16

75

93

35

A7

SISRLWHSLLRHLLH

19±1

19±4

23±3

>16

4

76

100

100

A8

KNFKKLMKKVASVL

>50

>50

>400

8

4

51

16

97

A9

SFSKWMGKLKNIFKK

>50

>50

>400

8

8

50

18

32

A10

LLRHCLRRIRDRLV

>50

>50

>400

16

8

70

56

67

A11

KWRSKIKKIMRTFK

>50

>50

>400

16

16

46

11

32

A12

GLLGRLAKLLANS

>50

>50

>400

16

16

49

1

3

A13

VFRQWQKIMRRLVRR

>50

>50

>400

>16

16

49

2

5

LL–III[g]

VNWKKILGKIIKVVK

6.0±0.5

15±3

>200

4‐8

4

74

99

72

B1

ANWKKWIGKVIKLVK

5.5±0.8

12±2

>200

4

4

70

99

77

B2

NWKKILGKILDHLAC

7.0±1.4

6.7±0.5

322±27

>16

8

68

94

100

B3

ANWKKILKRLCDI

22±0.5

28±5

166±4

>16

16

71

62

99

B4

NWKKILGKICR

>50

>50

>400

4

4

49

51

99

B5

KNWKKIIKKVVK

>50

>50

>400

4

16

35

11

99

B6

VNVWKKIGRLVKIVK

>50

>50

>400

8

4

60

50

74

B7

NEWKKIKKIIKIVK

>50

>50

>400

16

16

49

24

28

B8

KWRQLGKKIIKVAK

>50

>50

>400

16

16

51

12

99

B9

NWKKIRKLGKVVKKI

>50

>50

>400

16

16

40

28

80

B10

VVNNWKKKIIKVIK

>50

>50

>400

>16

>16

48

3

66

B11

DWHKIGKKVIKVIK

>50

>50

>400

>16

>16

53

14

99

B12

KWNNILGKLGKLAR

>50

>50

>400

>16

>16

46

4

14

B13

NVVGRLGKIVKIVK

>50

>50

>400

>16

>16

46

1

30

B14

NPKVFLKKIIKVVK

>50

>50

>400

>16

>16

54

0

0

B15

ADVWKKVIKVIK

>50

>50

>400

>16

>16

42

2

16

B16

WRGKIGKIIKAVK

>50

>50

>400

>16

>16

60

16

21

B17

NWKKILGRLGEKG

>50

>50

>400

>16

>16

26

0

13

B18

KNWKKIVHDIKNS

>50

>50

>400

>16

>16

38

1

14

B19

NWKKILGKVIDDMKM

>50

>50

>400

>16

>16

58

16

95

B20

DKFSEKLGKIIKIVK

>50

>50

>400

>16

>16

62

5

51

DLL‐III

vnwkkilgkiikvvk

5.0±0.7

14.5±2.0

>200

4

2

74

n.d.

n.d.

DA1

fakkffkkfakfafk

7.9±0.3

15.0±2.3

>200

4

4

71

n.d.

n.d.

DB1

anwkkwigkviklvk

6.2±1.1

13.1±2.8

>200

4

2

71

n.d.

n.d.

[a] All peptides were synthesized with C‐terminal amidation. [b] IC50 was determined after 72 h incubation at 37 °C in DMEM high glucose medium supplemented with 10 % FBS. [c] HC50 was measured on human red blood cells in 10 mM phosphate buffer saline, pH 7.4, 25 °C. Triton X‐100 was used as a positive control. [d] MIC was determined after incubation for 16–20 h at 37 °C in MH medium. [e] Circular dichroism spectra were measured at concentration 100 μg/mL of peptides in 10 mM phosphate buffer, pH 7.4 in a presence of 5 mM DPC. Percentage of α‐helical structure was calculated by DichroWeb. [f] Fluorescein leakage from phosphatidyl choline (PC) or phosphatidyl glycerol (PG) vesicles was measured in buffer (10 mM TRIS, 107 mM NaCl, pH 7.4) in the presence of 10 μg/mL of peptides. 0.012 % Triton in buffer was used as positive control. [g] Parent peptide lasioglossin III (LL‐III) used for PDGA was synthesized for comparison. n.d.– not determined.